Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma

This multicentre cohort study (n=387) found 43% of patients with stage III to IV melanomas treated with anti–PD-1 developed a chronic immune-related adverse event (most commonly affecting non-visceral organs) with only 14% resolving at last follow-up, although most were low grade

Source:

JAMA Oncology